Hill-Rom Holdings, Inc. (HRC) Receives Average Rating of “Buy” from Analysts

Hill-Rom Holdings, Inc. (NYSE:HRC) has been given an average rating of “Buy” by the ten research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $104.13.

Separately, Zacks Investment Research downgraded Hill-Rom from a “buy” rating to a “hold” rating and set a $111.00 price target on the stock. in a research note on Wednesday, December 5th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund increased its position in shares of Hill-Rom by 8,755.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,308,056 shares of the medical technology company’s stock valued at $26,000 after buying an additional 2,281,991 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in shares of Hill-Rom in the 4th quarter valued at $48,000. Captrust Financial Advisors increased its position in shares of Hill-Rom by 166.3% in the 4th quarter. Captrust Financial Advisors now owns 783 shares of the medical technology company’s stock valued at $69,000 after buying an additional 489 shares in the last quarter. IMS Capital Management bought a new stake in shares of Hill-Rom in the 3rd quarter valued at $71,000. Finally, Bronfman E.L. Rothschild L.P. increased its position in shares of Hill-Rom by 47.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 907 shares of the medical technology company’s stock valued at $80,000 after buying an additional 293 shares in the last quarter. Institutional investors and hedge funds own 84.22% of the company’s stock.

HRC stock opened at $104.24 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.25 and a current ratio of 1.70. The firm has a market capitalization of $6.95 billion, a PE ratio of 21.95, a P/E/G ratio of 1.81 and a beta of 0.96. Hill-Rom has a twelve month low of $81.82 and a twelve month high of $108.10.

Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, January 25th. The medical technology company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.04. The company had revenue of $683.50 million for the quarter, compared to the consensus estimate of $676.39 million. Hill-Rom had a return on equity of 21.23% and a net margin of 7.21%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.92 EPS. On average, analysts expect that Hill-Rom will post 5.04 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 22nd will be paid a $0.21 dividend. The ex-dividend date is Thursday, March 21st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.81%. This is an increase from Hill-Rom’s previous quarterly dividend of $0.20. Hill-Rom’s dividend payout ratio is 16.84%.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Article: How Do Tariffs Affect Trade Balances?

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply